<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Evry_Project_Biosensor skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Evry/Project/Biosensor</SPAN></H1><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="row"><DIV class="side-menu"><NAV class="navbar navbar-default" role="navigation"><DIV class="navbar-header"><DIV class="brand-wrapper"><BUTTON type="button" class="navbar-toggle" style="background-color:  #3f51b5;"><SPAN class="sr-only">Toggle navigation</SPAN></BUTTON></DIV></DIV><DIV class="side-menu-container" id="side-navigation"><UL class="nav navbar-nav"><LI class="panel panel-default dropdown" id="project-menu"><A data-toggle="collapse" href="#dropdown-project"> Project </A></LI><LI id="project_description"><A href="https://2015.igem.org/Team:Evry/Description">Overview</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Project/Chassis">Chassis choice</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Project/Encapsulation">Environment modulation</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Project/Biosensor">Hypoxia Bio-sensor</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Design">Proof of concept</A></LI></UL></DIV></NAV></DIV><LI class="panel panel-default dropdown" id="software-menu"><A data-toggle="collapse" href="#dropdown-software"> Antigen prediction </A></LI><LI><A href="https://2015.igem.org/Team:Evry/Software"><SPAN style="font-size:5%; color: transparent;">o</SPAN>Overview</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Software/Pipeline">Pipeline</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Software/Predictions">Prediction</A></LI></DIV></DIV><LI class="panel panel-default dropdown" id="practices-menu"><A data-toggle="collapse" href="#dropdown-practices"> Practices </A></LI><LI><A href="https://2015.igem.org/Team:Evry/Practices">Introduction</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Practices/State">Funding state of art</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Practices/Innovative">Innovative funding</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Practices/Society">Society perception</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Practices/Conclusion">Conclusion</A></LI></DIV></DIV><LI class="panel panel-default dropdown" id="achievements-menu"><A data-toggle="collapse" href="#dropdown-achievements"> Achievements </A></LI><LI><A href="https://2015.igem.org/Team:Evry/Medals">Medal fulfillment</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Collaborations">Collaborations</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Parts">Parts</A></LI></DIV><LI class="panel panel-default dropdown" id="notebook-menu"><A data-toggle="collapse" href="#dropdown-nb"> Notebook </A></LI><LI><A href="https://2015.igem.org/Team:Evry/Notebook">Day notes</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Protocols">Protocols</A></LI><LI class="panel panel-default dropdown" id="team-menu"><A data-toggle="collapse" href="#team-dropdown"> Team </A></LI><LI><A href="https://2015.igem.org/Team:Evry/Team">Members</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Attributions">Attributions</A></LI><LI><A href="https://2015.igem.org/Team:Evry/Acknowledgements">Acknowledgements</A></LI><DIV class="container"><DIV class="side-body" id="content-body"><DIV class="page-header"><H1>Tumor hypoxia bio-sensor</H1></DIV><SECTION class="page-section"><P class="text-justify">Hypoxia is tumor specific and represent a target for therapy. Up to 60 % percent of advanced solid tumors are characterized by hypoxia areas (0). Cancer cells present in these hypoxic regions are resistant to both chemotherapy and radiotherapy (1) and must be targeted by hypoxia-selective therapy. These cells are exposed to a very low oxygen tension of pO2 &lt; 10 mmHg, equivalent to &lt; 1.3% O2 in vitro (1).</P><P class="text-justify">Besides conferring resistance to cancer treatments, hypoxia also promotes tumor progression and metastasis. Hypoxia up-regulates over 80 genes associated with tumor progression, glycolysis, angiogenesis and metastasis (2) through HIF activity. Patients with a high proportion of hypoxic cell have low survival rate after surgical resection of the primary tumor (3). As 90 % of cancer deaths are attributed to metastatic spreading (3), targeting hypoxic cells could have a deep impact on reducing metastasis and the overall survival.</P><P class="text-justify">In order to detect this tumor hypoxic environment, we implemented a hypoxia bio-sensor in the yeast S. cerevisiae.</P></SECTION><SECTION class="page-section"><H2>Design of the hypoxia bio-sensor</H2><P class="text-justify">The choice of the right promoter is crucial in a bio-sensor design. Yeasts are facultative anaerobes that can naturally detect very low oxygen concentration with the corresponding promoters already present. However, these promoters need an addition fermentable carbon for induction, like ADH2 (4, 5). On the contrary, our system is intended to be used in vivo after encapsulation in alginate beads, without fermentable carbon source. Thus, we cloned the CMV minimal promoter as an inducer of the hypoxia gene reporter. Then, we need a Hypoxia Response Element (HRE) to start transcription factor binding to our CMV minimal promoter. HRE are DNA sequence that enhance transcription activity when the Hypoxia inducing Factor (HIF) binds to it. We assembled 4 HRE sequences ahead of the CMV minimal promoter to increase transcription in presence of hypoxia. The HRE was derived from the human HRE ahead of EPO promoter, as the EPO/HRE was more strongly induced than VEGF/HRE (6) by HIF in presence of hypoxia.</P><P class="text-justify">HIF transcription factors are composed of two sub-units. The α-subunits of the HIF transcription factors are degraded by proteasomal pathways during normoxia but are stabilized under hypoxic conditions (6). On the contrary, the beta-subunit of HIF is always expressed and maintained stable in the cytosol. We codon optimized the human HIF-alpha and HIF-beta for yeast and cloned these proteins in yeast S. cerevisiae under control of GAL1, a galactose inducible promoter.</P><P class="text-center"><STRONG> Figure 1 : Hypoxia inducible promoter</STRONG></P><P class="text-justify">To measure the activity of the bio-sensor, the gene reporter RFP was expressed under control of this HRE-CMV promoter. We used cobalt, a transition metal, to induce hypoxia. Cobalt mimics hypoxia by causing the stabilization of HIF-α (7).</P><P class="text-justify">Cloning steps were successful as showed sequencing data and colony PCR (figure 2). To remove the promoter GAL1 from our plasmid pYGG1 and replace it with the HRE/CMV promoter, we performed site-directed mutagenesis. First, we amplified the plasmid around GAL1 to remove it. Then, we phospholyrated with a kinase the blunt ends, we added DpnI to remove the template DNA and we ligated with T4 kinase. Colony PCR followed by digestion confirmed the successful assembly by golden gate:</P><P class="text-center"><STRONG> Figure 2: Colony PCR for biosensor 2 (HIF alpha and beta) and for biosensor 3 (HRE-CMV-RFP)</STRONG></P><P class="text-justify">Due to yeast autofluorescence in the red channel, we were not able to perform a fluorescence measurement with the Red Fluorescent Protein We will further characterize our bio-sensor with a LacZ assay instead of RFP. </P></SECTION><SECTION class="page-section"><H2>Inducing apoptosis in hypoxic environment</H2><P class="text-justify">We have a way to detect hypoxia area to locate tumor cells, now it’s time to destroy them.
In order to kill hypoxic tumor cells, we created a yeast secretion system for perforin and granzyme B under control of our hypoxia bio-sensor. Perforin is a pore-forming enzyme, allowing granzyme B to enter the cell. Granzyme B is a serine protease capable of inducing cell apoptosis by caspase activation. Co-expressed, these enzymes have proven their potential to induce cancer cell death :</P><UL><IL><P class="text-justify"><STRONG>A.</STRONG> In vitro delivery of granzyme B to colon cancer cells with perforin resulted in caspase 3 activation and features of apoptosis in those cells : chromatin condensation, nucleus fragmentation and internucleosomal DNA fragmentation (8)</P></IL><IL><P class="text-justify"><STRONG>B.</STRONG> Recombinant Granzyme B and perforin co-expressed in E. coli induced apoptosis and directly inhibited the growth of human laryngeal cancer Hep-2 cells in vitro (9)</P></IL></UL><P class="text-center"><STRONG>Figure 3 : Yeast encapsulated secreting perforine and granzyme B upon hypoxia detection</STRONG></P><P class="text-justify">For optimal conditions of translation, we placed both proteins on the same mRNA under control of the CMV minimal promoter. The Internal Ribosome Entry Site IRES URE2, effective in yeast, was placed ahead of the second protein to ensure two translations on the same mRNA.</P><P class="text-justify">Two different secretion signal, Matalpha leader peptide and BGL2 signal peptide, were fused to each protein to avoid internal recombination during expression.</P><P class="text-justify">Sequencing data showed the correct cloning of all the constructions producing Granzyme B and perforine. In vitro characterization remains to be done with these constructions.</P></SECTION><SECTION class="page-section"><P class="text-justify"><STRONG>References</STRONG></P><DIV style="font-size: 80%;"><P class="text-justify">0. Mees G, Dierckx R, Vangestel C, Van de Wile C, Molecular imaging of hypoxia with radiolabelled agents. 2009, Eur J Nucl Med Mol Imaging ;36:1674-1686</P><P class="text-justify">1. J. Martin Brown &amp; William R. Wilson, Exploiting tumour hypoxia in cancer treatment, Nature Reviews Cancer 4, 437-447 (June 2004) | doi:10.1038/nrc1367</P><P class="text-justify">2. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P, Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervixn, Cancer Res 1996, 56:4509-4515.</P><P class="text-justify">3. Gupta GP, Massague J, Cancer metastasis: building a framework. Cell, 2006, 127:679-695</P><P class="text-justify">4. K Weinhandl, M Winkler, A Glieder and A Camattari, Carbon source dependent promoters in yeasts, Microbial Cell Factories 2014, doi: 10.1186/1475-2859-13-5</P><P class="text-justify">5. Passoth V, Cohn M, Schäfer B, Hahn-Hägerdal B, Klinner U, Analysis of the hypoxia-induced ADH2 promoter of the respiratory yeast Pichia stipitis reveals a new mechanism for sensing of oxygen limitation in yeast, 2003, Yeast ;20(1):39-51.</P><P class="text-justify">6. Post DE and EG Van Meir, Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells, Nature Gene Therapy (2001) 8, 1801–1807</P><P class="text-justify">7. Yong Yuan, G Hilliard, T Ferguson and D E Millhorn, Cobalt Inhibits the Interaction between Hypoxia-inducible Factor-α and von Hippel-Lindau Protein by Direct Binding to Hypoxia-inducible Factor-α, 2003, The Journal of Biological Chemistry, 278, 15911-15916.</P><P class="text-justify">8. Vermijlen D, Froelich CJ, Luo D, Suarez-Huerta N, Robaye B, Wisse E, Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells. 2001, Cancer Immunol Immunother ;50(4):212-7.</P><P class="text-justify">9.  Li X, Zhang G, An G, Liu S, Lai Y, Expression, purification and anticancer analysis of GST-tagged human perforin and granzyme B proteins in human laryngeal cancer Hep-2 cells. 2014, Protein Expr Purif ;95:38-43. doi: 10.1016/j.pep.2013.11.009.</P></DIV></SECTION></DIV></DIV><DIV id="toTop"><SPAN class="scrolltext">To top</SPAN></DIV></BODY></HTML>